This is a multicenter, randomized, double-blind trial, comparing clinical outcomes after the
administration of high-dose dexamethasone versus placebo in patients undergoing heart surgery
with the use of cardiopulmonary bypass. The primary endpoint is the occurrence of major
complications (including all-cause mortality, myocardial infarction, stroke, renal failure,
and prolonged mechanical ventilation) in the first 30 days after surgery.